Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - The company achieved a significant reduction in losses, with a total revenue of 129.47 million yuan in 2024, representing a year-on-year increase of 13.32% [1] - The net profit attributable to shareholders was a loss of 201.38 million yuan, a reduction in loss by 127.58 million yuan compared to the previous year, attributed to cost reduction and efficiency improvements [1] - The company is focusing on expanding its revenue matrix through its main product, Aikening, and diversified business operations [1][2] Revenue Growth and Business Development - The company is actively promoting Aikening for new indications, with clinical trials for maintenance therapy and immune reconstitution failure approved by the National Medical Products Administration [2] - There is a significant unmet clinical need in the immune reconstitution failure area, with over 200,000 patients in China, indicating potential for future commercialization [2] - The company is exploring new technologies in the small nucleic acid field, with a candidate drug for IgA nephropathy, FB7013, entering the IND-enabling stage [2] High-End Generic Drugs and Future Projections - The company is making breakthroughs in high-end generic drugs, with FB4001 expected to be approved in the US by 2025 and FB3002's application accepted for review [3] - Revenue projections for 2025-2027 are 161 million yuan, 190 million yuan, and 223 million yuan, with year-on-year growth rates of 24.0%, 18.4%, and 17.2% respectively [3][5] - The net profit attributable to shareholders is projected to be -182 million yuan, -120 million yuan, and -176 million yuan for the same period [3][5] Financial Metrics - The company reported a revenue of 114 million yuan in 2023, with a growth rate of 34.8% [5] - The latest diluted EPS is projected to improve from -0.88 yuan in 2023 to -0.49 yuan in 2025 [5] - The company’s total market capitalization is approximately 3,206.39 million yuan, with a closing price of 8.56 yuan as of May 7 [6]

证券研究报告：电力设备 | 公司点评报告 发布时间：2025-05-08 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 86.20 | | --- | --- | | 总股本/流通股本（亿股）6.46 | / 6.46 | | 总市值/流通市值（亿元）557 | / 557 | | 52 周内最高/最低价 | 108.73 / 64.17 | | 资产负债率(%) | 37.4% | | 市盈率 | 18.11 | | 第一大股东 | 宁波梅山保税港区艾思 | | | 睿投资管理有限公司 | 研究所 分析师:杨帅波 SAC 登记编号:S1340524070002 Email:yangshuaibo@cnpsec.com 德业股份(605117) 逆变器出货高增，储能电池包业务快速成长 l 投资要点 事件：2025 年 4 月 29 日，公司发布 2024 年年报和 2025 年一季 报。 2024 年公司营收 112.1 亿元，同比+49.8%；归母净利润 29.6 亿 元，同比+65.3%；其中 2024Q4 公司营收 31.9 亿元，同环比分别 +176.5%/-2 ...

证券研究报告：电力设备 | 公司点评报告 发布时间：2025-05-08 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 26.61 | | --- | --- | | 总股本/流通股本（亿股）0.84 | / 0.84 | | 总市值/流通市值（亿元）22 | / 22 | | 52 周内最高/最低价 | 42.29 / 23.53 | | 资产负债率(%) | 24.0% | | 市盈率 | 45.10 | | 第一大股东 | 傅仕涛 | 研究所 分析师:杨帅波 SAC 登记编号:S1340524070002 Email:yangshuaibo@cnpsec.com 科威尔(688551) 氢能测试设备业务：不及预期，持续研发储备。2024 年氢能测试 设备业务营收 1.0 亿元，同比-15.1%，毛利率 46.9%，同比-0.1pct， 业绩不及预期主要是氢能产业的发展和标准体系的完善仍需要一定 时间。国家能源局于 2025 年 4 月 30 日发布《中国氢能发展报告 （2025）》，政策的顶层设计有望进一步强化，我们认为氢能产业景气 度有望逐步落地。 l 盈利预测 ...

分析师:杨帅波 SAC 登记编号:S1340524070002 Email:yangshuaibo@cnpsec.com 科威尔(688551) 业绩不及预期，静待氢能产业景气回升 证券研究报告：电力设备 | 公司点评报告 发布时间：2025-05-08 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 26.61 | | --- | --- | | 总股本/流通股本（亿股）0.84 | / 0.84 | | 总市值/流通市值（亿元）22 | / 22 | | 52 周内最高/最低价 | 42.29 / 23.53 | | 资产负债率(%) | 24.0% | | 市盈率 | 45.10 | | 第一大股东 | 傅仕涛 | 研究所 l 投资要点 事件：2025 年 4 月 25 日，公司发布 2024 年年报和 2025 年一季 报。 2024 年公司营收 4.8 亿元，同比-9.6%；归母净利润 0.5 亿元， 同比-58.1%；其中 2024Q4 公司营收 1.0 亿元，同环比分别-41.9%/- 18.0%，归母净利润-0.03 亿，同环比分别-106.2%/-126 ...

Investment Rating - The report maintains a "Buy" rating for the company, with an expected relative return of over 20% within the next six months [6][17]. Core Views - The company's revenue for Q1 2025 was 26.577 billion yuan, a year-on-year decrease of 14.14%, while the net profit attributable to the parent company was 1.93 billion yuan, a year-on-year increase of 3.66%. The net profit excluding non-recurring items was 1.896 billion yuan, reflecting a year-on-year growth of 17.01% [1][3]. - The decline in electricity generation and a slight decrease in electricity prices contributed to the revenue drop. The total electricity generation was 51.384 billion kWh, down approximately 8.51% year-on-year, and the average on-grid electricity price was about 505.71 yuan/MWh, a decrease of about 0.71% [2][3]. - The decrease in coal prices significantly improved the company's profitability, with a gross margin of 10.7%, an increase of 2.3 percentage points year-on-year. The average closing price of coal was 760 yuan/ton, down 164 yuan/ton year-on-year [3]. Financial Summary - The company plans to inject high-quality thermal power assets from its parent group, with the target assets having an operational installed capacity of approximately 16 GW, which will account for 26.85% of the company's total installed capacity by the end of 2024 [4]. - The report revises the profit forecast for 2025-2026, estimating net profits attributable to the parent company at 6.4 billion yuan, 7 billion yuan, and 7.4 billion yuan for 2025-2027, respectively, with corresponding P/E ratios of 9.1, 8.4, and 8.0 [4]. - The financial data indicates a projected revenue of 110.138 billion yuan for 2025, with a growth rate of -2.53% [5][11].

Investment Rating - The report maintains a "Buy" rating for the company [7][9] Core Insights - The company reported a revenue of 11.21 billion yuan in 2024, representing a year-on-year increase of 49.8%, with a net profit of 2.96 billion yuan, up 65.3% year-on-year [4][11] - The inverter business saw a revenue of 5.56 billion yuan in 2024, growing by 25.4% year-on-year, while the energy storage battery pack business experienced a significant growth of 177.2% year-on-year, reaching 2.45 billion yuan [5][6] - The company is expanding its product offerings in emerging markets, particularly in energy storage solutions, which are expected to drive future growth [5][6] Financial Performance Summary - The company’s revenue projections for 2025, 2026, and 2027 are 14.80 billion yuan, 19.90 billion yuan, and 24.65 billion yuan respectively, with corresponding net profits of 3.68 billion yuan, 4.65 billion yuan, and 6.24 billion yuan [7][11] - The projected PE ratios for 2025, 2026, and 2027 are 15, 12, and 9 times respectively, indicating a favorable valuation trend [7][11] - The company’s gross margin and net margin for Q1 2025 were reported at 37.2% and 27.5%, showing improvements in profitability [4]

精智达（688627.SH）：半导体业务 爆发，新型显示业务再突破 | 2025 | 年 5 | 月 | 8 | 日 | | --- | --- | --- | --- | --- | | 推荐/维持 | | | | | | 精智达 | 公司报告 | | | | ——2024 年报业绩点评 事件： 2025 年 4 月 25 日，精智达发布 2024 年度报告：公司 2024 年实现营业收入 8.03 亿元，同比增长 23.83%；归母净利润 0.80 亿元，同比下降 30.71%；扣 非归母净利润 0.69 亿元，同比下降 18.37%。 点评： 公司 2024 年度营收同比增长 23.83%，扣非归母净利润同比减少 18.37%，毛 利率短期下滑，半导体业务发展势头强劲。2024 年报告期内，公司实现营业 收入 8.03 亿元，同比增长 23.83%；扣非归母净利润 0.69 亿元，同比下降 18.37%。公司毛利率达 32.82%，同比下降 7.55pct。主要系收入结构战略调 整，毛利率在爬坡阶段，导致整体毛利率有所下滑。分业务来看，新型显示器 件检测实现营收 5.53 亿元，同比减少 2.09%，毛 ...

发布时间：2025-05-08 证券研究报告：公用事业 | 公司点评报告 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 7.16 | | --- | --- | | 总股本/流通股本（亿股）16.23 | / 16.23 | | 总市值/流通市值（亿元）116 | / 116 | | 52 周内最高/最低价 | 10.64 / 6.34 | | 资产负债率(%) | 66.7% | | 市盈率 | 23.64 | | 第一大股东 | 上海其辰企业管理有限 | | 公司 | | 研究所 分析师:杨帅波 SAC 登记编号:S1340524070002 Email:yangshuaibo@cnpsec.com 协鑫能科(002015) 持续优化能源资产，看好能源服务业务的持续开拓 l 投资要点 事件：2025 年 4 月 25 日，公司发布 2024 年年报和 2025 年一季 报。 2024 年公司营收 98.0 亿元，同比-5.4%；归母净利润 4.9 亿元， 同比-46.9%；其中 2024Q4 公司营收 22.4 亿元，同环比分别+60.4%/- 21.2%，归母净利 ...

证券研究报告：公用事业 | 公司点评报告 发布时间：2025-05-08 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 利润端：费用率下降，盈利能力提升。2025Q1 公司毛利率、净利 率分别23.3%/10.2%，同比分别+0.5pct/+1.6pcts，公司主要费用中， 销售费用率（0.7%）和研发费用率（0.02%）有所下降，管理费用率 （5.4%）和财务费用率（6.3%）下降较多，四项费用率总体下降 4.2pcts，有利于提升公司的盈利能力。 能源资产业务：持续拓展热电联产、新能源资产等业务。截止 2024 年底 ，并 网运 营总装 机 5871.01MW ，其 中燃 机热 电联 产 2017.14MW，燃煤热电联产 203MW，光伏发电（含集中式和分布式） 2022.27MW，风电 817.85MW，垃圾发电 149MW，储能 661.75MW。此外， 公司控股持有浙江建德协鑫抽水蓄能有限公司，建德抽蓄电站装机规 模 2400MW，项目稳步推进中。 能源服务业务：聚焦节能和交易服务。2024 年能源服务业务营 收 11.9 亿元，同比+337.25%，其中节能服务业务营收 7.8 亿元 ...

公司报告 | 年报点评报告 巨星科技（002444） 证券研究报告 24 年全年业绩高增，积极布局应对关税挑战 事件：公司发布年报，2024 年实现营业收入约 147.95 亿元，同比增加 35.37%；归母净利润 23.04 亿元，同比增加 36.18%。 点评： 24 年全年：毛利率/净利率分别 32%/16%，同比+0.21/+0.48pct。全年销售 / 管 理 / 研 发 / 财 务 费 用 率 分 别 为 6.59%/6.2%/2.47%/-0.89% ，同比 -1.2/-0.9/-0.5/+1.0pct。 24Q4：实现营收 37.12 亿元，同比+60%，环比-15.31%；实现归母净利润 3.68 亿元，同比+98.55% ，环比-50.36% ；Q4 毛利率/净利率分别为 30.89%/10.43%，同比-2.77pct/+2.6pct，环比-2.02pct/-6.72pct。 25Q1：实现营收 36.56 亿元，同比+10.59%，环比-1.5%；实现归母净利润 4.61 亿元，同比+11.44%，环比+25.14%。实现毛利率/净利率分别为 30.31%/13.19%，同比-1.07 ...